Floatz logo

ASPARAGINASE

Recurrent Childhood Acute Lymphoblastic Leukemia

Therapeutic Advances in Childhood Leukemia Consortiumprotein_peptidePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Recurrent Childhood Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BBB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
ETOPOSIDE
Martin Schrappe
Phase 3BBB

View all 45 →

Same molecule, other indications

ASPARAGINASE is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
lymphoblastic lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →